InvestorsHub Logo
Followers 13
Posts 61
Boards Moderated 0
Alias Born 08/16/2017

Re: Bright Boy post# 374571

Wednesday, 05/05/2021 1:40:06 AM

Wednesday, May 05, 2021 1:40:06 AM

Post# of 688918
In her presentation (Nicks YouTube link), Linda Liau provides an updated 3yr survival stat @ 28.2% for the entire phase 3 ITT population.

The 49% figure you reference may be confused with the below data point from the recent blinded publication in the JTM: https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-018-1507-6

For patients with methylated MGMT (n?=?131), mOS was 34.7 months from surgery, with a 3-year survival of 46.4%.



Encouraging stats nonetheless.

Wavelengthy
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News